Christina Yau

Christina Yau

UNVERIFIED PROFILE

Are you Christina Yau?   Register this Author

Register author
Christina Yau

Christina Yau

Publications by authors named "Christina Yau"

Are you Christina Yau?   Register this Author

60Publications

1916Reads

7Profile Views

The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.

JNCI Cancer Spectr 2018 Oct 8;2(4):pky067. Epub 2019 Jan 8.

Department of Surgery, University of California San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncics/pky067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649825PMC
October 2018

The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.

JNCI Cancer Spectr 2018 Oct 8;2(4):pky067. Epub 2019 Jan 8.

Department of Surgery, University of California San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncics/pky067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649825PMC
October 2018

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

J Med Imaging (Bellingham) 2018 01 23;5(1):011014. Epub 2017 Dec 23.

University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1117/1.JMI.5.1.011014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741993PMC
January 2018

Discovery of internalizing antibodies to basal breast cancer cells.

Protein Eng Des Sel 2018 01;31(1):17-28

Department of Anesthesia and Perioperative Care, University of California, San Francisco Rm 3C-38, Zuckerberg San Francisco General Hospital and Trauma Center, 1001 Potrero Ave, San Francisco, CA 94110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/protein/gzx063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283401PMC
January 2018

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

Breast Cancer Res Treat 2017 Nov 4;166(2):593-601. Epub 2017 Aug 4.

Department of Biosciences and Nutrition, Karolinska Institutet, Hälsovägen 7, 141 83, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4428-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668340PMC
November 2017

Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.

Breast Cancer Res Treat 2017 01 4;161(1):41-50. Epub 2016 Nov 4.

Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-4041-3DOI Listing
January 2017

Adaptive Randomization of Neratinib in Early Breast Cancer.

N Engl J Med 2016 Jul;375(1):11-22

From University of California, San Francisco (J.W.P., C.Y., L.J.V., N.M.H., M.B.B., A.J.C., M.M., J.L., S.E.D., G.L.H., L.J.E.), and QuantumLeap Healthcare Collaborative (M.P.), San Francisco, Buck Institute for Research and Aging, Novato (C.Y.), University of California, Davis, Davis (M.H.), University of California, San Diego, San Diego (A.M.W., R.S., T.H.), and University of Southern California, Los Angeles (D.T.) - all in California; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.C.L., C.I.); University of Minnesota, Minneapolis (D.Y., T.C.H.), and Mayo Clinic, Rochester (J.C.B.) - both in Minnesota; M.D. Anderson Cancer Center, Houston (W.F.S., L.P., S.L.M., D.A.B.), University of Texas Southwestern Medical Center, Dallas (D.M.E., B.B.H.), and Berry Consultants, Austin (A.S., D.A.B.) - all in Texas; Gemini Group, Ann Arbor, MI (J.P.); University of Pennsylvania, Philadelphia (A.D.); Oregon Health and Sciences University, Portland (S.Y.C., K.A.K.); Swedish Medical Center, Seattle (H.G.K.); University of Chicago (R.N.) and Loyola University (K.S.A.) - both in Chicago; Inova Fairfax Hospital, Falls Church, VA (K.K.E.); University of Denver, Denver (A.D.E.); Mayo Clinic, Scottsdale (D.W.N.), and University of Arizona, Tucson (J.E.L., R.K.V.) - both in Arizona; University of Kansas, Lawrence (Q.J.K.); and Emory University, Atlanta (W.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558PMC
July 2016

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

N Engl J Med 2016 Jul;375(1):23-34

From University of California, San Francisco (UCSF) (H.S.R., C.Y., L.J.V., M.B.B., N.M.H., A.J.C., C.E., J.L., S.E.D., G.L.H., L.J.E.), and QuantumLeap Healthcare Collaborative (M.P.), San Francisco, Buck Institute for Research and Aging, Novato (C.Y.), University of California, Davis, Davis (M.H.), University of California San Diego, San Diego (A.M.W., R.S.), and University of Southern California, Los Angeles (D.T.) - all in California; University of Chicago (O.I.O., R.N.), and Loyola University (K.S.A.), Chicago; University of Pennsylvania, Philadelphia (A.D.); Gemini Group, Ann Arbor, MI (J.P.); University of Texas M.D. Anderson Cancer Center, Houston (W.F.S., L.P., S.L.M., D.A.B.), UT Southwestern Medical Center, Dallas (D.M.E., B.B.H.), and Berry Consultants, Austin (A.S., D.A.B.) - all in Texas; University of Minnesota, Minneapolis (D.Y.), and Mayo Clinic, Rochester (J.C.B., T.C.H.) - both in Minnesota; Swedish Medical Center, Seattle (H.G.K.); Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.C.L., C.I.); University of Kansas, Lawrence (Q.J.K.); University of Arizona, Tucson (J.E.L., R.K.V.), and Mayo Clinic, Scottsdale (D.W.N.) - both in Arizona; Oregon Health and Sciences University, Portland (S.Y.C., K.A.K.); University of Denver, Denver (A.D.E.); Inova Fairfax Hospital, Falls Church, VA (K.K.E.); and Emory University, Atlanta (W.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259561PMC
July 2016

An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer.

Cancer Res 2016 04 26;76(7):1733-45. Epub 2016 Feb 26.

Department of Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2325-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907268PMC
April 2016

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.

JAMA Oncol 2016 Mar;2(3):395-6

Department of Surgery, University of California San Francisco.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4840DOI Listing
March 2016

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Breast Cancer Res Treat 2016 Feb 13;155(3):521-30. Epub 2016 Feb 13.

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3701-7DOI Listing
February 2016

FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.

Breast Cancer Res Treat 2015 Nov 12;154(1):23-32. Epub 2015 Oct 12.

Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA, 94945, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3589-7DOI Listing
November 2015

Rethinking the Standard for Ductal Carcinoma In Situ Treatment.

JAMA Oncol 2015 Oct;1(7):881-3

Department of Surgery, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.2607DOI Listing
October 2015

DGCR8 is essential for tumor progression following PTEN loss in the prostate.

EMBO Rep 2015 Sep 23;16(9):1219-32. Epub 2015 Jul 23.

The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California - San Francisco, San Francisco, CA, USA Center for Reproductive Sciences, University of California - San Francisco, San Francisco, CA, USA Department of Urology, University of California - San Francisco, San Francisco, CA, USA Department of Anatomic Pathology, University of California - San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15252/embr.201439925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576988PMC
September 2015

Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.

PLoS One 2014 7;9(2):e88309. Epub 2014 Feb 7.

Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0088309PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917875PMC
May 2015

Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers.

Breast Cancer Res Treat 2011 Apr 12;126(3):803-10. Epub 2011 Jan 12.

Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA 94945, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-011-1345-1
Publisher Site
http://dx.doi.org/10.1007/s10549-011-1345-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337964PMC
April 2011

Ageing, oxidative stress and cancer: paradigms in parallax.

Nat Rev Cancer 2008 Nov;8(11):875-9

Christopher C. Benz and Christina Yau are at the Buck Institute for Age Research, Novato, California 94945, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc2522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603471PMC
November 2008

Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.

Mol Pharmacol 2007 Jun 28;71(6):1525-34. Epub 2007 Mar 28.

Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA 94945, USA.

View Article

Download full-text PDF

Source
http://molpharm.aspetjournals.org/cgi/doi/10.1124/mol.107.03
Publisher Site
http://dx.doi.org/10.1124/mol.107.034090DOI Listing
June 2007

Novel pathways associated with quinone-induced stress in breast cancer cells.

Drug Metab Rev 2006 ;38(4):601-13

Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, Novato, CA 94945, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1080/0360253060095939
Publisher Site
http://dx.doi.org/10.1080/03602530600959391 DOI Listing
January 2007

Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.

Int J Biochem Cell Biol 2005 May;37(5):1130-44

Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA 94945, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biocel.2004.09.006DOI Listing
May 2005